INTRODUCTION
The primary objective of European regulation is to safeguard public health, encouraging the development of the pharmaceutical industry of the EU. Prior to marketing a medicinal product in the EU, a marketing authorization (MA) (product license) must be obtained. The company (more specifically "Marketing Authorization Holder") responsible for placing the medicinal product on the market must be established within the EEA (Iceland, Liechtenstein, Norway and the Member States of the European Union). European regulation has established and harmonized many aspects of regulating the production, distribution, and use of medicines in the EU (1) .
A major and important step was taken in 1995 by creating the European agency for the evaluation of medicinal products (European Medicines Evaluation Agency, EMA) and the establishment of a Centralized procedure, leading to a single EU wide evaluation and approval of new medicines (2) .
HISTORY
Need for the initiation of the regulation of pharmaceuticals by the impact of the Thalidomide disaster in the early 1960s. Thalidomide is a sedative designed to prevent morning sickness in pregnant women. But result of the use of this drug lead to birth of thousands of deformed babies. This tragedy exposed the inadequacies of safety control mechanisms. In a time where pharmaceutical scientific research progressed and international trade flows increased, the existing regulatory regimes were inadequate to face the nature of the risk involved (2) .
In 1965, the first European piece of legislation in the pharmaceuticals sector, the regulation (EC) was pursuing three main lines of action:
1) It clarified what a "medicinal product" was considered to be;
2) A drug would be approved for marketing, if it shows its safety, effectiveness and therapeutic value with proper documentation;
3) Laid down a number of common rules guiding testing requirements and labeling (2) (3) .
After this in 1975, a new wave of legislative intervention came and regulation (EC) approved three changes:
1) It developed a set of detailed common rules to standardize the tests and trials that medicinal products were subject to in the European Community.
2) A multi-state mutual recognition procedure was established, whereby a company which had received authorization to market a certain medicine in a Member State could seek the recognition of that authorization in at least five other Member States.
3) A Committee for Proprietary Medicinal Products (CPMP), including representatives of the Commission and national authorities, was created with the objective of supervising the multi-state application process and submit an opinion on whether medicines subject to that procedure complied with the requirements laid down by Council Directive 65/65/EEC (2). Out of 253 applications 175 got marketing authorization and 63 are definite refusals (2,4).
In 1986 multi-state procedure was introduced by Directive 83/570/ EEC, the council reformed many important aspect of the previous procedure which has been established by Directive 75/319/EEC.
Changes made were,
1. Member states must in future take into due consideration the initial authorization, save in exceptional cases when they refer reasoned objectives to the opinion of the committee.
2. To make the procedure more attractive and effective, the minimum member states concerned has been reduced from 5 to 2, and firms have at their disposal direct access to the committee.
3. To reach a decision with full knowledge of all the aspects, the concerned member states have at their disposal a detailed description of the content of the initial authorization in the form of a "Summary of Product Characteristics" as well as critical evaluation report prepared by the original country, at least in the case of new medicines.
Result of this all change in the procedure is that, in between 1986 to Feb. 1988 the numbers of dossiers submitted were 36 which cover 198 individual national applications, which is more as compared to previous applications (4). This is shown in Table 2 below. OBJECTIVES This paper was prepared with the following objectives.
• To understand Marketing Authorization procedures and types of applications.
• Selection of the process and basic requirements to get medicinal product into the EU market.
• The structure of Marketing Authorization process according to EU.
RESEARCH METHODOLOGY Type of Study
This was an exploratory study to understand the Drug Registration and Marketing Authorization Procedures in EU.
Data Collection
The study is based mainly on the basis of data collected from various sources like various regulatory agencies such as EMA, European Economic Council (EEC) etc. The data was also collected from available literature in journal articles published.
DISCUSSION

PROCEDURES FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS IN EU MARKET:
1. CENTRALIZED PROCEDURE
MUTUAL RECOGNITION PROCEDURE
3. DECENTRALIZED PROCEDURE 4. NATIONAL PROCEDURE (5).
CENTRALIZED PROCEDURE
As per the regulation (EC) No 726/2004, Centralized procedure is describe for marketing application of medicinal products, for which only one application, single evaluation and single authorization required for marketing medicinal product into entire community market. By this procedure medicinal product can be put into all member states.
Application for this type of authorization is directly send to EMA (6-7).
Applications of medicinal product are processed by following ways, which is shown in Figure 1 (6,8-9).
Admissibility of application
At least 7 month before the submission of application, applicant should inform EMA about the submission of application and give estimate of month of application. After discussion with the Committee for medicinal products for human use (CHMP), EMA will inform applicant for whether application is acceptable or not. If applicant is willing to apply for multiple applications then applicant must inform EMA about the submission before at least 4 months.
Before actual start of procedure rapporteur and corapporteur are appointed by the CHMP members and EMA (6).
Dossier
Dossier submitted to EMA and rapporteur, co-rapporteur both parallel.
1 full copy of dossier, 2 additional copy of module 1 & 2 including draft Summary of product characteristics (SmPC), labeling and package leaflet (PL) in English, 1 electronic copy of module 1 & 2 (6).
Payment of fees
Payment of fees should be done within 45 days of notification. The invoice will be sent to the billing address indicated by the applicant and will contain clear details of the product and procedures involved, the type of fee, the amount of the fee, the bank account to where the fee should be paid and the due date for payment (6).
Conditional marketing authorization
Request for accelerated assessment can be submitted at any time of prior to the submission of application. Applicant can apply for accelerated assessment procedure if he proves that the medicinal product is in major public health interest and therapeutically effective. Request has to be send within 10 working days in advance of the actual start of the evaluation procedure.
The timetable for the accelerated procedure is reduced to 150 days (6).
Renewal of marketing authorization
After marketing authorization expiry if applicant wants to continue sale the drug into the market then renewal of the marketing authorization is important. For the renewal of the marketing authorization applicant must apply before six month advance of the expiry of medicinal product in market. For this procedure required fees should submit within 45 days of notification date (6).
Schematic representation of Centralized procedure (6):
Start of the marketing authorization procedure.
80
Receipt of assessment report from rapporteur and co-rapporteur and EMA send this assessment report to applicant as a preliminary conclusion.
100 Rapporteur, Co-Rapporteur other CHMP members and EMA receive comments from Members of the CHMP (incl. peer reviewers).
115 Receipt of draft list of questions from Rapporteur and CoRapporteur, as discussed with the peer reviewers, by CHMP members and EMA.
120 CHMP adopts the list of questions as well as the overall conclusions and review of the scientific data to be sent to the applicant by the EMA.
CLOCK STOP (for Good Manufacturing Practice (GMP)/Good Laboratory Practice (GLP)/Good Clinical Practice (GCP) inspection)
121 Submission of the responses, including revised summary of product characteristics labeling and package leaflet texts in English, and restart of the clock. In general the following standard timetable will apply:
DAY ACTION
150
EMA sends joint Assessment Report to the applicant making it clear that it only their preliminary conclusions and that it is for information only.
170
Deadline for comments from CHMP Members to be sent to Rapporteur and Co-rapporteur, EMA and other CHMP Members.
180 CHMP discussion and decision on the need for adoption of a list of "outstanding issues" and/or an oral explanation by the applicant. If an oral explanation is needed, the clock is stopped to allow the applicant to prepare the oral explanation.
181
Restart the clock and oral explanation (if needed).
181 to 210 Final draft of summary of product characteristics, labeling and package leaflet in English sent by applicant to the rapporteur and Co-rapporteur, EMA and other CHMP members.
After adoption of a CHMP opinion, the preparation of the annexes to the Commission Decision is carried out in accordance with the following timetable: 
Flow chart of centralized procedure
Insert Flow char for centralized procedure
MUTUAL RECOGNITION PROCEDURE
This procedure is use to obtain marketing authorization in more than one member state where the medicinal product is already authorized in any member state at the time of application.
After first marketing authorization of medicinal product approved by community, applicant may request for one or more member states marketing authorization. After getting first marketing authorization, it is easier to get for further member states because medicinal product is already exist in European market and it helps to prove that product is therapeutic effective. 
Action following the submission of the application
Day -14
Submission the dossier to CMSs and validation. RMS circulates the AR to CMSs.
Day 0 RMS starts the procedure
Day 50
Comments to the RMS and applicant by CMSs.
Day 60
Applicants response document to CMSs and RMS
Until Day 68
RMS send assessment of response document to CMSs.
Day 75
Remaining comments from CMSs to RMS and applicant. A break-out session can be organised between day 73 -80).
Day 85
CMSs send any remaining comments to RMS and applicant. 
DECENTRALIZED PROCEDURE
This procedure is used to obtain marketing authorization in more than one member state but at the time of application medicinal product should not be approved in any member state.
Decentralized procedure is consisting of majorly five steps;
1. Pre-procedural step 2. Assessment step I 3. Assessment step II 4. Discussion at coordinal group level 5. National marketing authorisation step (10).
Decentralized procedure is as follows:
PRE-PROCEDURAL STEP I
Before Day -14 Applicant discussions with RMS and RMS allocates procedure no.
Day -14
Submission of the dossier to the RMS and CMSs.
Assessment step I
Day 0 RMS starts the procedure
Day 70
RMS forwards the Preliminary Assessment Report (PrAR) to CMSs
Until Day 100
CMSs send their comments to the RMS
Until Day 105
Consultation between RMS and CMSs and applicant. If consensus not reached RMS stops the clock and ask applicant to respond questions and supplementation to dossier.
Clock-off period
Applicant sends the response document to the RMS and CMSs within a recommended period of 3 months, which could be extended if justified.
Day 106
Valid submission of the response of the applicant received. RMS restarts the procedure.
Day 106 -120
RMS updates PrAR to prepare Draft Assessment Report (DAR) draft SPC, draft labeling and draft PL to CMSs.
Day 120
If consensus reached procedure closed and start of national step. 
ASSESSMENT STEP II
Day 210 (Day 90)
Closure of the procedure.
Day 210 (at the latest)
If consensus was not reached at day 210, points of disagreement will be referred to the Co-ordination group for resolution.
Day 270 (at the latest)
Final decision by Co-ordination Group with referral to CHMP/CVMP for arbitration in case of unsolved disagreement.
NATIONAL STEP III
Day
110/125/155/215/275
Applicant sends high quality national translations of SPC, labeling and PL to CMS and RMS.
Day 135/150/180/240
Granting of national marketing authorisation in RMS and CMSs if no referral to the Co-ordination group.
Day 300
Granting of national marketing authorisation in RMS and CMSs if positive conclusion by the Coordination group and no referral to the CHMP/ CVMP.
Flow chart of the Decentralized Procedure
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NATIONAL PROCEDURE
If the applicant want to get the marketing authorization in only one member state then application should be made to national competent authority of respective member state where marketing authorization is sought. In this case while taking the national marketing approval, medicinal product should not be approved in other member state under same sponsor. 
